Statement from FDA Commissioner Scott Gottlieb, M.D., on new policies to reduce the ability of brand drug makers to use REMS programs as a way to block timely generic drug entry, helping promote competition and access
If your email program has trouble displaying this email, view it as a web page |
U.S. Food and Drug Administration |
Comments
Post a Comment